Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CARsgen Therapeutics

www.carsgen.com

Latest From CARsgen Therapeutics

Yet Another Myeloma CAR-T Therapy Makes It Onto EMA’s PRIME

Only two of seven applications for entry into the European Medicines Agency’s priority medicines scheme for getting treatments for unmet medical need to patients faster were successful last month.

Research and Development Strategies Europe

ASH Preview: BCMA-Targeting CAR-Ts And Bispecifics Hog The Spotlight

Some of the most anticipated data at ASH are for therapies targeting BCMA in multiple myeloma, including a next-gen CAR-T from bluebird and Celgene as well as Amgen's novel BiTE, but an update from China's Legend Biotech and J&J could steal the show.

Clinical Trials Cancer

Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A

China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.

Deals Financing

Finance Watch: VC Interest Lags At Early Stage – 'Hogwash' Or Evidence-Based?

Venture Capital Edition: A VC investor at a recent conference said it's "hogwash" that venture capitalists aren't interested in funding early-stage biopharma, but the trend toward large financings – such as the $220m raised to date by Rubius – and 2017 investment data suggest otherwise.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • CARsgen Therapeutics
  • Senior Management
  • Zonghai Li, MD, PhD, CEO
    HuaMao Wang, PhD, COO
    HaiOu Chen, EVP, Fin.
    Leigh Hsu, PhD, SVP, Bus. Dev,
  • Contact Info
  • CARsgen Therapeutics
    Phone: 21 64501828
    388 Yindu Rd.
    Building B
    Shanghai,
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register